Understanding Telix, page-1062

I agree. Share price is expecting solid half yearly numbers but for the share price to continue another step up the market will need an approval dropped.
I watched an interview with Garry the portfolio manager of Montgomery small companies fund and he explained how he values biotech companies. Upcoming approvals are given next to no value in current share price until they are approved. Market sees it as too risky to assign value.
I do think a post 30/6 market update is required on these major catalysts when numbers are released.
When speaking with CB that’s why my questions focused on timing of these major catalysts. I expect the EU UK approval of illuccix to be know very shortly after the 45 days from AGM date so early July. Zircaix is the big one but was assured if approved sales by November / December.